Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to collect and assess information on proper use of valaciclovir regarding safety and efficacy of long-term use in suppressive therapy for subjects with recurrent genital herpes.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Acyclovir; Valacyclovir

Criteria

Inclusion Criteria:

• Subjects who started suppressive therapy for recurrent genital herpes for the first time

Exclusion Criteria:

• Subjects with a history of hypersensitivity to the ingredients of VALTREX or aciclovir